HRT and TRT are both forms of hormone therapy, but they're built around different hormones, different patient populations, and different bodies of clinical evidence. Understanding the real distinctions helps set realistic expectations for either treatment.

Figure 2. HRT and TRT differ in their target hormone, typical patient population, and evidence base.
Figure 2. HRT and TRT differ in their target hormone, typical patient population, and evidence base.

Who Each Therapy Is Designed For

HRT is the term generally used for estrogen (with or without progesterone) replacement in women, most often during perimenopause or after menopause, when the ovaries significantly reduce hormone production. TRT is the term used for testosterone replacement in men with clinically confirmed low testosterone.

These population distinctions are strong general rules, not absolute ones. Some men experience hormone imbalances that involve estrogen or other hormones beyond testosterone, and a smaller, more specialized use of testosterone therapy exists for postmenopausal women with low sexual desire — though no testosterone product is currently FDA-approved for women in the U.S.

Different Goals, Different Mechanisms

The core difference in purpose: HRT aims to restore a balance of multiple hormones (primarily estrogen and progesterone) to relieve the broad set of symptoms associated with menopause. TRT has a narrower, more singular goal — restoring testosterone specifically to address the symptoms of clinically diagnosed deficiency.

Diagnostic Criteria Differ Too

For TRT, diagnostic thresholds vary somewhat by medical society — the Endocrine Society uses a lower total testosterone threshold (around 264 ng/dL) than the American Urological Association (under 300 ng/dL), while other societies use a higher cutoff (around 350 ng/dL). What all guidelines agree on: a diagnosis of low testosterone should never rest on a single blood draw. It requires consistent, repeated low levels on morning fasting labs, combined with disruptive symptoms.

For HRT, diagnosis is typically more symptom-driven, since hormone fluctuation during perimenopause can make lab values less consistent as a sole diagnostic tool. A clinical history of irregular periods, hot flashes, and other menopausal symptoms often carries more diagnostic weight than a single estrogen or FSH level.

Administration Overlaps, but Isn't Identical

Both therapies are available as oral tablets, patches, gels, and injections. TRT additionally includes pellet implants and lozenges, while HRT additionally includes vaginal rings, suppositories, and creams designed for localized symptom relief.

The Evidence Base Differs in Important Ways

HRT has been studied extensively, most notably through the large Women's Health Initiative (WHI) trial. Current research has refined earlier blanket warnings into a more nuanced "timing hypothesis" — risk and benefit depend heavily on a woman's age and years since menopause at the time HRT is started.

TRT's evidence base centers more on confirming a clear diagnosis before treatment, since testosterone therapy given without confirmed deficiency has not shown the same consistent benefit as treatment in men who are truly deficient.

The Bottom Line

HRT and TRT are not simply "the same treatment for different sexes." They replace different hormones, are diagnosed using different criteria, and rest on different (though both substantial) bodies of clinical evidence. Neither should be started based on symptoms alone or lab values alone — both require the combination, confirmed by a qualified provider.